General MedicationsINTRAVENOUSStandard
ASPARLAS
CALASPARGASE PEGOL-MKNL
Standard Dose
3750UNITS/5ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ASPARLAS is listed in Drugs@FDA under application 761102 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient CALASPARGASE PEGOL-MKNL Form and strength INJECTABLE;INTRAVENOUS - 3750UNITS/5ML Sponsor SERVIER PHARMA LLC Submission history Latest submission status date: 2023-11-29 00:00:00.
Structured Monograph
Clinical summary
Approval overview ASPARLAS is listed in Drugs@FDA under application 761102 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient CALASPARGASE PEGOL-MKNL Form and strength INJECTABLE;INTRAVENOUS - 3750UNITS/5ML Sponsor SERVIER PHARMA LLC Submission history Latest submission status date: 2023-11-29 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.